NORGESIC Drug Patent Profile
✉ Email this page to a colleague
Which patents cover Norgesic, and what generic alternatives are available?
Norgesic is a drug marketed by Bausch and is included in one NDA.
The generic ingredient in NORGESIC is aspirin; caffeine; orphenadrine citrate. There is one drug master file entry for this compound. Three suppliers are listed for this compound. Additional details are available on the aspirin; caffeine; orphenadrine citrate profile page.
AI Deep Research
Questions you can ask:
- What is the 5 year forecast for NORGESIC?
- What are the global sales for NORGESIC?
- What is Average Wholesale Price for NORGESIC?
Summary for NORGESIC
| US Patents: | 0 |
| Applicants: | 1 |
| NDAs: | 1 |
| Raw Ingredient (Bulk) Api Vendors: | 1 |
| Clinical Trials: | 1 |
| Patent Applications: | 14 |
| DailyMed Link: | NORGESIC at DailyMed |
Recent Clinical Trials for NORGESIC
Identify potential brand extensions & 505(b)(2) entrants
| Sponsor | Phase |
|---|---|
| University of Baghdad | PHASE4 |
US Patents and Regulatory Information for NORGESIC
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Bausch | NORGESIC | aspirin; caffeine; orphenadrine citrate | TABLET;ORAL | 013416-003 | Oct 27, 1982 | DISCN | Yes | No | ⤷ Start Trial | ⤷ Start Trial | ⤷ Start Trial | ||||
| Bausch | NORGESIC FORTE | aspirin; caffeine; orphenadrine citrate | TABLET;ORAL | 013416-004 | Oct 27, 1982 | DISCN | Yes | No | ⤷ Start Trial | ⤷ Start Trial | ⤷ Start Trial | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
